Yogurt and Cardiometabolic Diseases: A Critical Review of Potential Mechanisms

被引:65
|
作者
Fernandez, Melissa Anne [1 ,2 ,3 ]
Panahi, Shirin [4 ]
Daniel, Noemie [1 ,2 ,3 ]
Tremblay, Angelo [1 ,3 ,4 ]
Marette, Andre [1 ,2 ,5 ]
机构
[1] Univ Laval, Heart & Lung Inst Quebec, Quebec City, PQ, Canada
[2] Univ Laval, Inst Nutr & Funct Foods, Quebec City, PQ, Canada
[3] Univ Laval, Fac Agr & Food Sci, Sch Nutr, Quebec City, PQ, Canada
[4] Univ Laval, Fac Med, Dept Kinesiol, Quebec City, PQ, Canada
[5] Univ Laval, Fac Med, Dept Med, Quebec City, PQ, Canada
关键词
bioactive peptides; cardiometabolic diseases; dairy; fermented dairy; foodmatrix; hypertension; microbiota; obesity; type; 2; diabetes; yogurt; CONJUGATED LINOLEIC-ACID; DAIRY PRODUCT CONSUMPTION; CHAIN FATTY-ACIDS; DOSE-RESPONSE METAANALYSIS; CARDIOVASCULAR RISK-FACTORS; INSULIN-RESISTANCE SYNDROME; ACTIVATED RECEPTOR-ALPHA; FERMENTED FOOD-PRODUCTS; BLOOD-PRESSURE; GUT MICROBIOTA;
D O I
10.3945/an.116.013946
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Associations between yogurt intake and risk of diet-related cardiometabolic diseases (CMDs) have been the subject of recent research in epidemiologic nutrition. A healthy dietary pattern has been identified as a pillar for the prevention of weight gain and CMDs. Epidemiologic studies suggest that yogurt consumption is linked to healthy dietary patterns, lifestyles, and reduced risk of CMDs, particularly type 2 diabetes. However, to our knowledge, few to no randomized controlled trials have investigated yogurt intake in relation to cardiometabolic clinical outcomes. Furthermore, there has been little attempt to clarify the mechanisms that underlie the potential beneficial effects of yogurt consumption on CMDs. Yogurt is a nutrient-dense dairy food and has been suggested to reduce weight gain and prevent CMDs by contributing to intakes of protein, calcium, bioactive lipids, and several other micronutrients. In addition, fermentation with bacterial strains generates bioactive peptides, resulting in a potentially greater beneficial effect of yogurt on metabolic health than nonfermented dairy products such as milk. To date, there is little concrete evidence that the mechanisms proposed in observational studies to explain positive results of yogurt on CMDs or parameters are valid. Many proposed mechanisms are based on assumptions that commercial yogurts contain strain-specific probiotics, that viable yogurt cultures are present in adequate quantities, and that yogurt provides a minimum threshold dose of nutrients or bioactive components capable of exerting a physiologic effect. Therefore, the primary objective of this review is to investigate the plausibility of potential mechanisms commonly cited in the literature in order to shed light on the inverse associations reported between yogurt intake and various cardiometabolic health parameters that are related to its nutrient profile, bacterial constituents, and food matrix. This article reviews current gaps and challenges in identifying such mechanisms and provides a perspective on the research agenda to validate the proposed role of yogurt in protecting against CMDs.
引用
收藏
页码:812 / 829
页数:18
相关论文
共 50 条
  • [21] Per- and polyfluoroalkyl substances and cardiometabolic diseases: A review
    Schillemans, Tessa
    Donat-Vargas, Carolina
    Akesson, Agneta
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 134 (01) : 141 - 152
  • [22] Racial/Ethnic Discrimination and Cardiometabolic Diseases: A Systematic Review
    Agbonlahor, Osayande
    DeJarnett, Natasha
    Hart, Joy L.
    Bhatnagar, Aruni
    McLeish, Alison C.
    Walker, Kandi L.
    JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES, 2024, 11 (02) : 783 - 807
  • [23] The metabolic and molecular mechanisms of α-mangostin in cardiometabolic disorders (Review)
    John, Oliver Dean
    Mushunje, Annals Tatenda
    Surugau, Noumie
    Guad, Rhanye Mac
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2022, 50 (03)
  • [24] Identification of potential new targets for the prevention and treatment of cardiometabolic diseases
    Moreno-Viedma, V.
    Amor, M.
    Sarabi, A.
    Bilban, M.
    Zeyda, M.
    Stulnig, T. M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (17-18) : 736 - 737
  • [25] Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives
    Feijoo-Bandin, Sandra
    Aragon-Herrera, Alana
    Rodriguez-Penas, Diego
    Portoles, Manuel
    Rosello-Lleti, Esther
    Rivera, Miguel
    Gonzalez-Juanatey, Jose R.
    Lago, Francisca
    FRONTIERS IN PHYSIOLOGY, 2017, 8
  • [26] Mechanisms of inflammatory microenvironment formation in cardiometabolic diseases: molecular and cellular perspectives
    Liu, Menghua
    Chen, Rumeng
    Zheng, Zhiwei
    Xu, Shuling
    Hou, Chunyan
    Ding, Yining
    Zhang, Mengling
    Bao, Meihua
    He, Binsheng
    Li, Sen
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2025, 11
  • [27] Advancing the communication of genetic risk for cardiometabolic diseases: a critical interpretive synthesis
    Law J.H.
    Sultan N.
    Finer S.
    Fudge N.
    BMC Medicine, 21 (1)
  • [28] Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases
    Sartor, R. B.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 : 27 - 36
  • [29] Mechanisms of action and biocontrol potential of Trichoderma against fungal plant diseases - A review
    Asad, Saeed Ahmad
    ECOLOGICAL COMPLEXITY, 2022, 49
  • [30] Potential therapeutic mechanisms of Draconis Resina in cardiovascular diseases-a narrative review
    Wang, Jing
    Tang, Xiusong
    Lan, Peng
    Liang, Bin
    Fang, Yu
    Li, Hongbo
    FRONTIERS IN PHARMACOLOGY, 2025, 16